AstraZeneca

Open: 70.33 Close: 70.47 Change: 0.14

Can you guess what an AI found about AstraZeneca.

This document will help you to evaluate AstraZeneca without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, deal, gene, therapy, sale, drug, Alexion, and the …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Company is largest drugmaker in China, which accounted for 13% of its revenue. Oncology continues to be its biggest source of revenue.

Today's News

Astrazeneca PLC ADR outperforms market despite losses on the day. AstraZeneca strikes $1 billion deal for Pfizer rare-disease gene therapies. AstraZeneca delivered forecast-beating profits and sales in the second quarter as a strong performance by its blockbuster cancer drugs offset the loss of COVID-19 vaccine sales. Company is largest drugmaker in China, which accounted for 13%. AstraZenecas Alexion unit has agreed to buy U.S. drug company Alexion for $39 billion in 2021. British company also said Sharon Barr, head of research and development at Alexion, would succeed. Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America. FDA review of eplonsen for ATTR polyneuropathy already underway and plans to file for regulatory approval in the EU and other countries later this year. Astrazeneca strikes $1 billion deal for pfizer rare-disease gene therapies. Deal gives AstraZeneca a group of early-stage gene therapies that target rare diseases. AstraZeneca shares were trading at 11,118 pence, up 3.91 percent. The company announced Thursday that it will sell its interest in the diabetes business to Astra. The Evansville Courier & Press reports (http://bit.ly/JTkHu6 ) that part of that deal calls for Astra AstraZeneca reported higher-than-expected revenue on strong sales of its cancer drugs. Oncology continues to be its biggest source, accounting for 39% of revenue.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, deal, gene, therapy, sale, drug, Alexion, and the most common words in the summary are: astrazeneca, news, best, pharma, company, event, late, . One of the sentences in the summary was: Oncology continues to be its biggest source of revenue.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #news #best #pharma #company #event #late.